Literature DB >> 8471553

Prognostic significance of proliferative activity and ploidy in node-negative breast cancers.

R Silvestrini1, M G Daidone, G Del Bino, M Mastore, A Luisi, G Di Fronzo, P Boracchi.   

Abstract

BACKGROUND: Cell kinetics and DNA ploidy have provided relevant information on the natural history of breast cancer. We assessed the prognostic role of proliferative activity and ploidy, alone and in association with tumor size, estrogen (ER) and progesterone (PgR) receptors. PATIENTS AND METHODS: In a series of 340 women with resectable node-negative breast cancers given local-regional therapy alone until relapse, proliferative activity was determined as the 3H-thymidine labeling index (3H-dT LI) and flow-cytometric S-phase cell fraction (FCM-S), as quantified by using different modeling systems. DNA ploidy, ER and PgR content were determined on frozen samples by FCM and by the dextran-coated charcoal absorption technique, respectively.
RESULTS: FCM-S estimates obtained by the different models were weakly associated with one another and to the corresponding 3H-dT LIs. Four-year relapse-free survival was significantly predicted by 3H-dT LI, ploidy and tumor size but not by FCM-S. Multiple regression analysis showed that 3H-dT LI, ploidy and tumor size retained their prognostic significance and that 3H-dT LI was the most significant indicator of relapse (p = 0.009).
CONCLUSIONS: The finding that 3H-dT LI and ploidy are weakly related and provide independent prognostic information could allow a more accurate identification of patients at different risk of relapse.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471553     DOI: 10.1093/oxfordjournals.annonc.a058458

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  8 in total

Review 1.  Prognosis and prediction of response in breast cancer: the current role of the main biological markers.

Authors:  A Ravaioli; L Bagli; A Zucchini; F Monti
Journal:  Cell Prolif       Date:  1998 Jun-Aug       Impact factor: 6.831

2.  Post-operative nomogram for predicting freedom from recurrence after surgery in localised breast cancer receiving adjuvant hormone therapy.

Authors:  Chafika Mazouni; Frédéric Fina; Sylvie Romain; Pascal Bonnier; L'houcine Ouafik; Pierre-Marie Martin
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-30       Impact factor: 4.553

3.  Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.

Authors:  A E Pinto; S André; J Soares
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

4.  Comparison between different cell kinetic variables in human breast cancer.

Authors:  F Barzanti; M Dal Susino; A Volpi; D Amadori; A Riccobon; E Scarpi; L Medri; L Bernardi; S Naldi; M Aldi; M Gaudio; W Zoli
Journal:  Cell Prolif       Date:  2000-04       Impact factor: 6.831

5.  Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma.

Authors:  A Bonetti; M Zaninelli; S Rodella; A Molino; L Sperotto; Q Piubello; F Bonetti; R Nortilli; M Turazza; G L Cetto
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre.

Authors:  R S Camplejohn; C M Ash; C E Gillett; B Raikundalia; D M Barnes; W M Gregory; M A Richards; R R Millis
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

7.  Is the thymidine labeling index a good prognostic marker in breast cancer?

Authors:  Ebru Sen-Oran; Vahit Ozmen; Ayhan Bilir; Neslihan Cabioglu; Mahmut Muslumanoglu; Abdullah Igci; Nese Guney; Mustafa Kecer
Journal:  World J Surg Oncol       Date:  2007-08-19       Impact factor: 2.754

8.  The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial.

Authors:  Sara Bravaccini; Giuseppe Bronte; Emanuela Scarpi; Sara Ravaioli; Roberta Maltoni; Anita Mangia; Maria Maddalena Tumedei; Maurizio Puccetti; Patrizia Serra; Lorenzo Gianni; Laura Amaducci; Nicoletta Biglia; Valentina Bounous; Angelo Virgilio Paradiso; Rosella Silvestrini; Dino Amadori; Andrea Rocca
Journal:  Ther Adv Med Oncol       Date:  2020-02-27       Impact factor: 8.168

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.